Medical advances in hepatitis D therapy: molecular targets
An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of the disease. Until re...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 September 2022
|
| In: |
International journal of molecular sciences
Year: 2022, Jahrgang: 23, Heft: 18, Pages: 1-12 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms231810817 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3390/ijms231810817 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1422-0067/23/18/10817 
|
| Verfasserangaben: | Amelie Vogt, Sabrina Wohlfart, Stephan Urban and Walter Mier |
| Zusammenfassung: | An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of the disease. Until recently, the only available therapy consisted of interferon-α, only eligible for a minority of patients. In July 2020, the EMA granted Hepcludex conditional marketing authorization throughout the European Union. This first-in-class entry inhibitor offers the promise to prevent the spread in order to gain control and eventually participate in curing hepatitis B and D. Hepcludex is an example of how understanding the viral lifecycle can give rise to new therapy options... |
|---|---|
| Beschreibung: | Gesehen am 15.11.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms231810817 |